Clay Siegall, Ph.D. is one of the founders of Seattle Genetics. The company was founded in 1998 and Dr. Siegall is the CEO. He is a scientist who focuses on cancer therapies. He has guided the company into the position of being the leader in the development of antibody-drug conjugates and secured the approval of the FDA for their product called Adcetris.
Seattle Genetics has collaborated with Takeda Pharmaceutical and become a global brand. They have received approval in over 65 countries. Dr. Siegall has additionally led the capital raising for Seattle Genetics and secured over $1.2 billion in private and public financing. Dr. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research before he helped found Seattle Genetics. He also worked for the National Institutes of Health and the National Cancer Institute.
Dr. Siegall has received numerous awards including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year. He has written over seventy publications and has fifteen patents. Dr. Siegall additionally has a Ph.D. in Genetics and a B.S. in Zoology.
As the CEO of Seattle Genetics Dr. Siegall studies therapies for cancer. His antibody-based therapies have resulted in a diverse pipeline including the development of Adcetris also known as brentuximab vedotin. The therapy was approved by the FDA in 2011.
Dr. Clay Siegall has also been incredibly successful in raising capital for Seattle Genetics. He admits that when he was in his twenties he thought he had all the answers. Now he understands you simply learn what you can in life. He believes that interactions with intelligent people bring expertise into his life. His strategy in business is the collaboration with the leaders of industry in the field of oncology drug development. His collaborations have extended his technological reach and given him the ability to find new resources and approaches. Dr. Siegall does everything he can to help cancer patients as much as possible.